American Society of Clinical Oncology

SHERPA: White

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. O'Reilly
    O'Reilly
  4. Saltz
    Saltz
  5. Bajorin
    Bajorin
  6. Kris
    Kris
  7. Hudis
    Hudis
  8. Morris
    Morris
  9. Rosenberg
    Rosenberg
  10. Robson
    Robson

Groups

  1. Department of Medicine (6413)
  2. Solid Tumor Oncology Division (5551)
  3. Survivorship Research (2002)
  4. Genitourinary Oncology Service (1770)
  5. Surgery (1646)
  6. Epidemiology and Biostatistics (1500)
  7. GSK Faculty (1390)
  8. Population Sciences Research Program (1385)
  9. Gastrointestinal Oncology Service (1358)
  10. Hematologic Malignancies, Division of (1286)
Search Within
Formats
  1. Meeting Abstract (6344)
  2. Journal Article (2591)
  3. Editorial (82)
  4. Review (70)
  5. Guidelines (55)
  6. Correspondence (51)
  7. Miscellaneous (4)
  8. Conference Paper (3)
Groups
  1. Department of Medicine (6413)
  2. Solid Tumor Oncology Division (5551)
  3. Survivorship Research (2002)
  4. Genitourinary Oncology Service (1770)
  5. Surgery (1646)
  6. Epidemiology and Biostatistics (1500)

More Groups

People
  1. Robert Motzer (451)
  2. Howard Scher (334)
  3. Eileen O'Reilly (310)
  4. Leonard Saltz (283)
  5. Dean Bajorin (280)
  6. Mark Kris (253)

More People

Years
  1. 2025 (308)
  2. 2024 (554)
  3. 2023 (580)
  4. 2022 (554)
  5. 2021 (504)
  6. 2020 (539)

More Years

Publications
  1. Journal of Clinical Oncology (8715)
  2. JCO Precision Oncology (174)
  3. Journal of Oncology Practice (124)
  4. American Society of Clinical Oncology Educational Book (112)
  5. JCO Clinical Cancer Informatics (54)
  6. JCO Oncology Practice (13)

More Publications

Results (9200)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Toxicity of sunitinib plus bevacizumab in renal cell carcinoma - Reply
    Journal Article

    Feldman, D. R.; Scappaticci, F. A.; Motzer, R. J.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea
    Journal Article

    Dang, C.; Lin, N.; Moy, B.; Come, S.; Sugarman, S.; Morris, P.; Abbruzzi, A.; Chen, C.; Steingart, R.; Patil, S.; more...
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • Reply to K. Dunleavy et al
    Journal Article

    Chadburn, A.; Noy, A.; Lee, J. Y.; Hyjek, E.; Banham, A. H.; Sparano, J. A.; Bhatia, K.; Cesarman, E.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • Weighing risks and benefits of postchemotherapy retroperitoneal lymph node dissection: Not so easy
    Journal Article

    Bosl, G. J.; Motzer, R. J.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • Histone deacetylase inhibition as a mechanism for the therapeutic effect of statins (3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors) in follicular lymphoma
    Journal Article

    Barker, C. A.; Yahalom, J.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • A six-panel PCR of both plasma and blood for EBV-DNA as tumor marker for nasopharyngeal carcinoma patients treated in the United States
    Meeting Abstract

    Weiss, J.; Xavier, M.; Tsai, D.; Arnoldi, S.; Sherman, E.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • Phase I/II study of sorafenib and temsirolimus for patients with recurrent glioblastoma (GBM) (NABTC 05-02)
    Meeting Abstract

    Wen, P. Y.; Cloughesy, T.; Kuhn, J.; Lamborn, K.; Abrey, L. E.; Lieberman, F.; Robins, H. I.; Wright, J.; Prados, M. D.; Gilbert, M.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • Efficacy of ipilimumab 10 mg/kg in advanced melanoma patients (pts) with good and poor prognostic factors
    Meeting Abstract

    Wolchok, J. D.; de Pril, V.; Linette, G.; Waterfield, W.; Gajewski, T.; Chiarion-Sileni, V.; Ibrahim, R.; Chin, K.; Hoos, A.; Hamid, O.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • Phase IIb/III double-blind randomized trial of BIBW 2992, an irreversible, dual inhibitor of EGFR and HER2 plus best supportive care (BSC) versus placebo plus BSC in patients with NSCLC failing 1-2 lines of chemotherapy (CT) and erlotinib or gefitinib (LUX-Lung1): A preliminary report
    Meeting Abstract

    Yang, C.; Hirsh, V.; Cadranel, J.; Chen, Y.; Park, K.; Kim, S.; Chao, T.; Oberdick, M.; Shahidi, M.; Miller, V.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • Cytokine changes in castrate metastatic prostate cancer (CPMC) patients (pts) treated with ipilimumab (Ipi)
    Meeting Abstract

    Yuan, J.; Orlandi, F.; Jefferson, M.; Li, H.; Gallardo, H.; Ku, G.; Wolchok, J.; Scher, H.; Allison, J.; Slovin, S. F.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save